EP2029624B1 - Peptide associé au rhumatisme articulaire aigu (parf) et son utilisation en tant que marqueur diagnostique - Google Patents

Peptide associé au rhumatisme articulaire aigu (parf) et son utilisation en tant que marqueur diagnostique Download PDF

Info

Publication number
EP2029624B1
EP2029624B1 EP07725777.2A EP07725777A EP2029624B1 EP 2029624 B1 EP2029624 B1 EP 2029624B1 EP 07725777 A EP07725777 A EP 07725777A EP 2029624 B1 EP2029624 B1 EP 2029624B1
Authority
EP
European Patent Office
Prior art keywords
peptide
collagen
binding
collagen binding
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP07725777.2A
Other languages
German (de)
English (en)
Other versions
EP2029624A1 (fr
Inventor
Gursharan S. Chhatwal
Patric D. Nitsche-Schmitz
Katrin Dinkla
Vanessa Barroso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Original Assignee
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum fuer Infektionsforschung HZI GmbH filed Critical Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Priority to EP07725777.2A priority Critical patent/EP2029624B1/fr
Publication of EP2029624A1 publication Critical patent/EP2029624A1/fr
Application granted granted Critical
Publication of EP2029624B1 publication Critical patent/EP2029624B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention relates to an isolated collagen binding peptide, comprising an amino acid sequence according to one of SEQ ID No. 3 to SEQ ID No. 15, and wherein said collagen binding peptide has a length of between 8 and 12 amino acids, for use in medicine.
  • Peptides associated with rheumatic fever (PARF) that, through their interaction with human collagen, plays a crucial role in the pathogenesis of rheumatic fever. PARF therefore represents a marker for rheumatic fever associated strains and provides a target for therapies, and in particular preventive therapies.
  • Acute rheumatic fever and the subsequent rheumatic heart disease are serious sequelae of streptococcal infections. It has been known for decades that Streptococcus pyogenes infection is a cause of this sequelae, but only recently it has been shown that other streptococcal species can also induce acute rheumatic fever in humans.
  • Acute rheumatic fever is one of the most serious diseases caused by streptococci and occurs as an autoimmune sequela following untreated or inadequately treated S. pyogenes pharyngitis ( A. L. Bisno, N Engl J Med 325, 783 (Sep 12,1991 ), M. McDonald, B. J. Currie, J. R. Carapetis, Lancet Infect Dis 4, 240 (Apr, 2004 )).
  • ARF and the subsequent rheumatic heart disease (RHD) remain significant causes of cardiovascular disease today (WHO, " Rheumatic fever and rheumatic heart disease - Report of an Expert Panel" (2004 )). The most devastating effects are on children and young adults in their most productive years.
  • GCS group C streptococci
  • GGS group G streptococci
  • WO 2004-071422 describes S. pyogenes serum opacity factor (SOF)- and S. dysgalactiae fibronectin-binding protein-based polypeptides, and antibody compositions and methods.
  • the compositions are regarded as effective in eliciting opsonic and/or protective antibodies specific for S. pyogenes and/or S. dysgalactiae and, consequently, as useful for the treatment, diagnosis, and monitoring of streptococcal infections, including S. pyogenes and S. dysgalactiae infections, and diseases associated with S. pyogenes and S. dysgalactiae infections, as well as associated autoimmune neurological disorders.
  • S. pyogenes serum opacity factor (SOF)- and S. dysgalactiae fibronectin-binding protein-based polypeptides and antibody compositions and methods.
  • the compositions are regarded as effective in eliciting opsonic and/or protective antibodies specific for
  • WO 03/033520 A2 describes cyclic peptides that are different from the ones of the present invention.
  • JP 10262698 describes a probe including a DNA fragment derived from S. pyogenes as a probe for diagnosing an infectious disease.
  • the probe is describes as useful for detection and identification of the S. pyogenes, which is a pathogen of pharyngitis, rheumatic fever, nephritis, erysipelas, scarlatina, septicemia, etc.
  • the probe is obtained by extracting a chromosome DNA from the S. pyogenes microbe, allowing the extracted chromosome DNA to be completely digested by a restriction enzyme Hind III, cloning the digested DNA and selecting a fragment manifesting a specific reactivity with the DNA of the microbe.
  • US 6,777,547 describes collagen-binding proteins Cpa1 and Cpa49 from S. pyogenes, and their corresponding amino acid and nucleic acid sequences as useful in the prevention and treatment of infection caused by group A streptococcal bacteria such as S. pyogenes. These proteins have been observed to bind to collagen, and methods are provided, such as by administration of the proteins or antibodies generated thereto, whereby streptococcal binding of collagen can be inhibited, and streptococcal infection can be greatly reduced.
  • the proteins are described as being advantageous because they may be used as vaccine components or antibodies thereof, and they may be administered to wounds or used to coat biomaterials in order to act as collagen blocking agents and reduce or prevent severe infection by group A streptococcal bacteria.
  • Cpa1 and Cpa49 are homologs of the collagen binding proteins CNA from Staphylococcus aureus and CNE from Streptococcus equi, and bind collagen through a mechanism that is different from PARF.
  • Kumar D et al in Kumar D, Kaur S, Grover A, Singal PK, Ganguly NK. An easy method for detection of rheumatic antigen(s) in rheumatic fever/rheumatic heart disease patients by dot-ELISA. Can J Cardiol. 1998 Jun;14(6):807-10 ) describe various monoclonal antibodies developed against human B cell alloantigen, e.g. the monoclonal antibody D8/17 which was found to be 100% specific for rheumatic fever/rheumatic heart disease patients from New York, but which identified only 62% to 68% in the north Indian population.
  • US 6,280,997 discloses a collection of 1166 protein sequences in the context with the isolation of an RPE cell membrane associated protein having alcohol dehydrogenase activity. Some of the peptides are described for use in the context of diagnosis. The shortest peptide has a length of 30 amino acids. None of these peptides were reported to have collagen binding activity.
  • M3 protein is identified as collagen-binding factor of M3 streptococci, whereas M18 isolates bind collagen through a hyaluronic acid capsule, revealing a novel function for M3 protein and capsule.
  • the object of the present invention is solved by providing an isolated collagen binding peptide, comprising an amino acid sequence according to one of SEQ ID No. 3 to SEQ ID No. 15, and wherein said collagen binding peptide has a length of between 8 and 12 amino acids, for use in medicine.
  • the following table shows the preferred PARF-peptides of the present invention, as well as their origins (full length-proteins, together with database Accession numbers). As can be seen from the sequences, position 1 appears to be rather flexible, whereas position 3, 4, 7 and 8 are highly conserved and important for an efficient binding of collagen: Protein Database Accession No. Sequence SEQ ID No. Species FOG AAT99868 ARYLQKLN SEQ ID No. 3 Streptococcus dysgalactiae subsp.
  • the inventors investigated the potential of different streptococcal species to interact with and to aggregate collagen, in order to understand the underlying mechanisms and to identify the involved bacterial components.
  • An S. pyogenes strain with high rheumatogenic potential was included as a positive control ( J. R. Carapetis, M. McDonald, N. J. Wilson. Lancet 366, 155 (JuI 9-15, 2005 )). All strains were tested for binding to radioactive collagen.
  • the collagen IV reactive mouse sera were pooled and antibodies against collagen IV and FOG1-A were determined before and after pre-absorption with FOG protein.
  • the serum titer against collagen IV remained almost unchanged after preabsorption, indicating lack of any cross-reactivity between anti-FOG and anti-collagen antibodies ( Figure 3B ).
  • sera from patients with ARF and healthy controls were tested for reactivity against N-terminal of M3 protein as well as FOG 1-A.
  • a six- to eight-fold increase of serum titers against FOG 1-A was observed with patients' sera as compared to control sera from healthy donors from the same geographic region ( Figure 3C ).
  • the motif described above plays a crucial role in rendering collagen an auto-antigen and subsequently in pathogenesis of rheumatic fever.
  • the peptide was therefore designated PARF (peptide associated with rheumatic fever). Since PARF is present not only in the surface protein of group A streptococci, but also in group C and G streptococci, the role of the GCS and GGS in rheumatic fever is now understandable. The results of this study have made clear that the induction of rheumatic fever cannot be uniquely associated with group A streptococcal infections, and that other streptococcal species play an equivalent or even more important role in the pathogenesis of rheumatic fever. These results have important diagnostic and therapeutic consequences.
  • the invention provides a collagen binding peptide for use in medicine, wherein said peptide includes non-peptide bonds.
  • peptide the inventors include not only molecules in which amino acid residues are joined by peptide (-CO-NH-) linkages but also molecules in which the peptide bond is reversed.
  • retro-inverso peptidomimetics may be made using methods known in the art, for example such as those described in Meziere et al (1997) J. Immunol. 159,3230-3237 . This approach involves making pseudopeptides containing changes involving the backbone, and not the orientation of side chains.
  • Retro-inverse peptides which contain NH-CO bonds instead of CO-NH peptide bonds, are much more resistant to proteolysis.
  • Peptides (at least those containing peptide linkages between amino acid residues) may be synthesized by the Fmoc-polyamide mode of solid-phase peptide synthesis as disclosed by Lu et al (1981) J. Org. Chem. 46, 3433-3436 , and references therein. Temporary N-amino group protection is afforded by the 9-fluorenylmethyloxycarbonyl (Fmoc) group. Repetitive cleavage of this highly base-labile protecting group is achieved by using 20 % piperidine in N, N-dimethylformamide.
  • Side-chain functionalities may be protected as their butyl ethers (in the case of serine threonine and tyrosine), butyl esters (in the case of glutamic acid and aspartic acid), butyloxycarbonyl derivative (in the case of lysine and histidine), trityl derivative (in the case of cysteine) and 4-methoxy-2,3,6-trimethylbenzenesulphonyl derivative (in the case of arginine).
  • glutamine or asparagine are C-terminal residues, use is made of the 4,4'-dimethoxybenzhydryl group for protection of the side chain amido functionalities.
  • the solid-phase support is based on a polydimethyl-acrylamide polymer constituted from the three monomers dimethylacrylamide (backbone-monomer), bisacryloylethylene diamine (cross linker) and acryloylsarcosine methyl ester (functionalizing agent).
  • the peptide-to-resin cleavable linked agent used is the acid-labile 4-hydroxymethyl-phenoxyacetic acid derivative. All amino acid derivatives are added as their preformed symmetrical anhydride derivatives with the exception of asparagine and glutamine, which are added using a reversed N, N-dicyclohexyl-carbodiimide/1hydroxybenzotriazole mediated coupling procedure.
  • Trifluoroacetic acid is removed by evaporation in vacuo, with subsequent trituration with diethyl ether affording the crude peptide.
  • Any scavengers present are removed by a simple extraction procedure which on lyophilization of the aqueous phase affords the crude peptide free of scavengers.
  • Reagents for peptide synthesis are generally available from Calbiochem-Novabiochem (UK) Ltd, Nottingham NG7 2QJ, UK.
  • Purification may be effected by any one, or a combination of, techniques such as size exclusion chromatography, ion-exchange chromatography and (usually) reverse-phase high performance liquid chromatography.
  • Analysis of peptides may be carried out using thin layer chromatography, reverse-phase high performance liquid chromatography, amino-acid analysis after acid hydrolysis and by fast atom bombardment (FAB) mass spectrometric analysis, as well as MALDI and ESI-Q-TOF mass spectrometric analysis.
  • FAB fast atom bombardment
  • the invention provides a collagen binding peptide for use in medicine wherein said peptide is a fusion protein.
  • Fusion proteins and methods for their construction are well known in the state of the art and can include genetic fusion of the peptide with an enzyme group (e.g. producing a color signal), a tag for purification (e.g. a His-tag), a chelating peptide, and the like.
  • an antibody or fragment thereof that is immunologically reactive with the collagen binding peptide of the present invention which also can be utilized in methods of treatment which involve inhibition of the attachment of the collagen binding peptide to collagen.
  • specific antibodies or fragments thereof against the collagen binding peptide could be generated that reacts with the collagen binding peptide in, for example, Western immunoblots and ELISA assays and which interferes with the binding of the peptide to collagen.
  • This antibody or fragment thereof can thus be used for specific agglutination assays to detect bacteria which express a collagen binding peptide.
  • Preferred in the context of the present invention is a monoclonal antibody that selectively (specifically) binds to the collagen binding peptide of the present invention, more particularly and preferably selectively to a peptide according to any of the sequence according to SEQ ID No. 3 to SEQ ID No. 15.
  • Most preferred is a monoclonal antibody which immunologically recognizes all of the sequences according to SEQ ID No. 3 to SEQ ID No. 15, and preferably specifically recognizes all of the sequences according to SEQ ID No. 3 to SEQ ID No. 15.
  • a "fragment" of a ligand in particular a fragment of an antibody, shall mean a moiety that is derived from the ligand that is still capable of binding to the respective cellular marker (for example, the collagen binding peptide).
  • the respective cellular marker for example, the collagen binding peptide.
  • antibodies are scFV-fragments and other antibody-derived peptides that can bind to the respective cellular marker.
  • the binding of the fragment leads to the same biological effect(s) as the binding of the full-length (or sized) ligand, preferably the inhibition of the collagen-binding of the peptide according to the invention.
  • the isolated peptides of the present invention can be prepared in a number of suitable ways known in the art including typical chemical synthesis processes to prepare a sequence of polypeptides.
  • nucleic acid e.g. polynucleotide
  • the nucleic acid according to the present invention may be DNA, cDNA, PNA, CNA, RNA or combinations thereof and it may or may not contain introns as long as it codes for the peptide.
  • peptides which contain naturally occurring amino acid residues joined by naturally occurring peptide bonds are encodable by a polynucleotide.
  • an expression vector capable of expressing a peptide according to the invention.
  • a variety of methods have been developed to operably link polynucleotides, especially DNA, to vectors for example via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.
  • Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors.
  • the DNA segment generated by endonuclease restriction digestion as described earlier, is treated with bacteriophage T4 DNA polymerase or E. coli DNA polymerase I, enzymes that remove protruding, 3'-single-stranded termini with their 3'-5'-exonucleolytic activities, and fill in recessed 3'-ends with their polymerizing activities.
  • the combination of these activities therefore generates blunt-ended DNA segments.
  • the blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase.
  • an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase.
  • the products of the reaction are DNA segments carrying polymeric linker sequences at their ends.
  • These DNA segments are then cleaved with the appropriate restriction enzyme and ligated to an expression vector that has been cleaved with an enzyme that produces termini compatible with those of the DNA segment.
  • Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc, New Haven, CN, USA.
  • a desirable way to modify the DNA encoding the polypeptide of the invention is to use the polymerase chain reaction as disclosed by Saiki et al (1988) Science 239,487-491 .
  • This method may be used for introducing the DNA into a suitable vector, for example by engineering in suitable restriction sites, or it may be used to modify the DNA in other useful ways as is known in the art.
  • the DNA to be enzymatically amplified is flanked by two specific primers which themselves become incorporated into the amplified DNA.
  • the said specific primers may contain restriction endonuclease recognition sites which can be used for cloning into expression vectors using methods known in the art.
  • the DNA (or in the case of retroviral vectors, RNA) is then expressed in a suitable host to produce a polypeptide comprising the compound of the invention.
  • the DNA encoding the peptide constituting the compound of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the peptide of the invention.
  • Such techniques include those disclosed in US Patent Nos.
  • DNA (or in the case of retroviral vectors, RNA) encoding the peptide constituting the compound of the invention may be joined to a wide variety of other DNA sequences for introduction into an appropriate host.
  • the companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.
  • the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression.
  • an expression vector such as a plasmid
  • the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognized by the desired host, although such controls are generally available in the expression vector.
  • the vector is then introduced into the host through standard techniques. Generally, not all of the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells.
  • One selection technique involves incorporating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance.
  • the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.
  • Host cells that have been transformed by the recombinant DNA are then cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which can then be recovered.
  • the present invention also describes a host cell transformed with a polynucleotide vector construct.
  • the host cell can be either prokaryotic or eukaryotic.
  • Bacterial cells may be preferred prokaryotic host cells in some circumstances and typically are a strain of E. coli such as, for example, the E. coli strains DH5 available from Bethesda Research Laboratories Inc., Bethesda, MD, USA, and RR1 available from the American Type Culture Collection (ATCC) of Rockville, MD, USA (No ATCC 31343).
  • Preferred eukaryotic host cells include yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human fibroblastic and kidney cell lines.
  • Yeast host cells include YPH499, YPH500 and YPH501 which are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA.
  • Preferred mammalian host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, monkey kidney-derived COS-1 cells available from the ATCC as CRL 1650 and 293 cells which are human embryonic kidney cells.
  • Preferred insect cells are Sf9 cells which can be transfected with baculovirus expression vectors.
  • Transformation of appropriate cell hosts with a DNA construct is accomplished by well known methods that typically depend on the type of vector used. With regard to transformation of prokaryotic host cells, see, for example, Cohen et al (1972) Proc. Natl. Acad. Sci. USA 69,2110 and Sambrook et al (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY . Transformation of yeast cells is described in Sherman et al (1986) Methods In Yeast Genetics, A Laboratory Manual, Cold Spring Harbor, NY . The method of Beggs (1978) Nature 275,104-109 is also useful.
  • reagents useful in transfecting such cells for example calcium phosphate and DEAE-dextran or liposome formulations, are available from Stratagene Cloning Systems, or Life Technologies Inc., Gaithersburg, MD 20877, USA. Electroporation is also useful for transforming and/or transfecting cells and is well known in the art for transforming yeast cell, bacterial cells, insect cells and vertebrate cells.
  • Successfully transformed cells i.e. cells that contain a DNA construct of the present invention
  • cells resulting from the introduction of an expression construct of the present invention can be grown to produce the polypeptide of the invention.
  • Cells can be harvested and lysed and their DNA content examined for the presence of the DNA using a method such as that described by Southern (1975) J. Mol. Biol. 98, 503 or Berent et al (1985) Biotech. 3, 208 .
  • the presence of the protein in the supernatant can be detected using antibodies as described below.
  • bacteria for example E. coli and Bacillus subtilis
  • yeasts for example Saccharomyces cerevisiae
  • filamentous fungi for example Aspergillus
  • plant cells animal cells and insect cells, as above.
  • a promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur.
  • Promoter sequences compatible with exemplary bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention.
  • Typical prokaryotic vector plasmids are pUC18, pUC19, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA, USA) and pTrc99A and pKK223-3 available from Pharmacia, Piscataway, NJ, USA.
  • the present invention provides an improved method for screening for ligands of the collagen binding peptide according to the present invention, comprising the steps of: a) incubating said peptide with a putative ligand, b) measuring a binding between said peptide and said putative ligand, and c) identifying said ligand, wherein said ligand inhibits collagen binding of said peptide, and wherein said ligand for example is an antibody or fragment thereof that is immunologically reactive with the collagen binding peptide.
  • these ligands can be identified based on the structural similarities of the collagen-binding peptide with other proteins. Examples for the generation of such ligands are described in the literature (as mentioned also herein) and well known to the person of skill.
  • the ligand will initially bind or attach to the collagen binding peptide.
  • the ligand can either bind directly or indirectly to the collagen binding peptide, i.e. via cofactors that can be present, such as certain ions or protein factors, that promote the attachment of the ligand to the collagen binding peptide, and therefore support the function of the ligand. "Binding" can occur via a covalent or non-covalent attachment of the ligand or group of ligands to the collagen binding peptide.
  • a first pre-selection of ligands can be performed, in which a non-binding ligand is screened in a second "round” of screening using a set of co-factors. If still no binding occurs, the ligand will be classified as "non-binding" and disregarded in further screenings.
  • Such pre-selection will be encompassed by the terms “screening”, “measuring” and/or “determining” in the general context of this invention.
  • a ligand that shows an in-vitro action should in vivo preferably not further interact with components of the patients' or test (model) organisms' body, e.g. within the bloodstream, lung and/or heart of the patient or test organism.
  • assays to determine a binding and biological effect of a ligand to a specific target are well known to the person skilled in the art and can be found, for example, in US patents 4,980,281 , 5,266,464 and 5,688,655 to Housey for phenotypic changes of cells after incubation with a screening ligand.
  • US 5,925,333 to Krieger at al. describes methods for modulation of lipid uptake and related screening methods.
  • Suitable tests for showing a biological effect of a ligand for the collagen binding peptide may include lytic assays that measure the release of intracellular contents (uric acid, potassium, phosphorus) into the extracellular compartment, fluorescence based assays (e.g. use of confocal fluorescent microscopy), viable cell counts, cellular proliferation assays, such as the BrdU proliferation assay or measuring of cellular calcium, and the like.
  • lytic assays that measure the release of intracellular contents (uric acid, potassium, phosphorus) into the extracellular compartment
  • fluorescence based assays e.g. use of confocal fluorescent microscopy
  • viable cell counts e.g. use of confocal fluorescent microscopy
  • cellular proliferation assays such as the BrdU proliferation assay or measuring of cellular calcium, and the like.
  • the method of screening according to the present invention can be performed in several different formats.
  • One embodiment is a method, wherein the assay is performed in vitro.
  • the screening assays of the present invention preferably involve the use of host cell-lines (as described above) and other cells, as long as these cells express the collagen binding peptide. How to produce such recombinant cells is well known to the skilled artisan and is further described above and in the respective literature.
  • An additional embodiment of the present invention relates to a method wherein the assay is performed in vivo in a mouse or rat.
  • the in vivo assay will not be substantially different from the above-mentioned in vitro assay.
  • a general screening assay for ligands of the collagen binding peptide will be provided in that the ligand to be tested is/are administered to a mouse or a rat. Then, it will be determined, if said ligand leads to an inhibition of the collagen binding activity, compared to the absence of the ligand to be tested, wherein a difference identifies a ligand which leads to an inhibition or reduction of the collagen binding activity.
  • these assays can be performed in other non-human mammals as well.
  • An additional embodiment of the present invention relates to a method according to the invention, wherein said ligand is selected from a library of naturally occurring or synthetic compounds which are randomly tested for binding to the collagen binding peptide.
  • libraries and the methods how to build up such a library, as well as methods for using these libraries for the screening of candidate ligands are well known to the person skilled in the art and further described in the respective literature. Furthermore, some of these libraries are commercially available.
  • the present invention contemplates high throughput screening of ligands for the collagen binding peptide.
  • the ligands as described above, and modifications of said ligands, including analogues, derivatives, fragments, active moieties, and the like, may be screened using methods and systems of the present invention.
  • said ligand is an antibody or fragment thereof that is immunologically reactive with the collagen binding peptide as described above.
  • the compound of interest is combined with one or more of the collagen binding peptides or fragments thereof and the degree of binding of the protein to collagen or other extracellular matrix proteins is measured or observed. If the presence of the compound results in the inhibition of protein-collagen binding, for example, then the compound may be useful for inhibiting streptococci in vivo or in vitro.
  • the method could similarly be used to identify compounds that promote interactions of streptococci with host molecules. The method is particularly useful for identifying compounds having bacteriostatic or bacteriocidal properties.
  • a synthetic reaction mixture for example, a synthetic reaction mixture, a cellular compartment (such as a membrane, cell envelope or cell wall) containing one or more of the collagen binding peptides or fragments thereof and a labeled substrate or ligand of the protein is incubated in the absence or the presence of a compound under investigation.
  • the ability of the compound to agonize or antagonize the protein is shown by a decrease in the binding of the labeled ligand or decreased production of substrate product.
  • Compounds that bind well and increase the rate of product formation from substrate are agonists.
  • Detection of the rate or level of production of product from substrate may be enhanced by use of a reporter system, such as a colorimetric labeled substrate converted to product, a reporter gene that is responsive to changes in the collagen binding peptide nucleic acid or protein activity, and binding assays known to those skilled in the art. Competitive inhibition assays can also be used.
  • a reporter system such as a colorimetric labeled substrate converted to product, a reporter gene that is responsive to changes in the collagen binding peptide nucleic acid or protein activity, and binding assays known to those skilled in the art.
  • binding assays known to those skilled in the art.
  • Competitive inhibition assays can also be used.
  • Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to the collagen binding peptide nucleic acid molecules or proteins or portions thereof and thereby inhibit their activity or bind to a binding molecule (such as collagen to prevent the binding of the collagen binding peptide nucleic acid molecules or proteins to its ligand.
  • a binding molecule such as collagen to prevent the binding of the collagen binding peptide nucleic acid molecules or proteins to its ligand.
  • a compound that inhibits the collagen binding peptide activity may be a small molecule that binds to and occupies the binding site of the collagen binding peptide, thereby preventing binding to cellular binding molecules, to prevent normal biological activity.
  • small molecules include, but are not limited to, small organic molecule, peptides or peptide-like molecules.
  • Other potential antagonists include antisense molecules.
  • Preferred antagonists include compounds related to and variants or derivatives of the collagen binding peptides or portions thereof.
  • the nucleic acid molecules described herein
  • a method for the production of a pharmaceutical formulation comprising the steps of: a) performing a screening method as above, and b) formulating the ligand as identified with a pharmaceutically acceptable carrier and/or excipient.
  • Such formulations therefore include, in addition to the ligand/antibody, a physiologically acceptable carrier or diluent, possibly in admixture with one or more other agents such as other antibodies or drugs, such as an antibiotic.
  • Suitable carriers include, but are not limited to, physiological saline, phosphate buffered saline, phosphate buffered saline glucose and buffered saline.
  • the ligand e.g.
  • the antibody may be lyophilized (freeze dried) and reconstituted for use when needed by the addition of an aqueous buffered solution as described above.
  • Routes of administration are routinely parenteral, including intravenous, intramuscular, subcutaneous and intraperitoneal injection or delivery. The administration can be systemic and/or locally.
  • Preferred pharmaceutical compositions as described comprise at least one peptide according to the present invention, or an antibody according to the present invention, and a pharmaceutically acceptable carrier as above.
  • a pharmaceutical preparation preferably in the form of a vaccine, that is effective against rheumatic fever, comprising an effective amount of a peptide according to the invention.
  • the vaccine can furthermore contain additional peptides and/or excipients to be more effective, as is explained herein.
  • these peptide(s) will still have an epitope structure that allows for the generation of antipeptide antibodies that are also effective against the PARF-containing bacterial proteins and peptides.
  • Examples for peptides that have been inactivated are those mutants as described and examined in the present examples and the Figures below, in particular in Figure 4F (substituents A 58 , Y 60 , L 64 , N 65 , LND 66 and YL 61 ).
  • the inactivated peptides can be used for an improvement of vaccines.
  • the inactivation of the PARF-sequence through the substitution of amino acids shall reduce the risk of an induction of an autoimmune reaction against collagen.
  • the inactive form should remain as homologous as possible to the PARF-sequence.
  • Single substitutions in positions 3, 7 or 8 of AXYLZZLN appear to be effective and are preferred.
  • Position 1 has proven to be comparably tolerant.
  • Suitable carriers include, but are not limited to, physiological saline, phosphate buffered saline, phosphate buffered saline glucose and buffered saline.
  • the ligand e.g. the antibody, may be lyophilized (freeze dried) and reconstituted for use when needed by the addition of an aqueous buffered solution as described above.
  • Routes of administration are routinely parenteral, including intravenous, intramuscular, subcutaneous and intraperitoneal injection or delivery. The administration can be systemic and/or locally.
  • the vaccine may be administered without adjuvant.
  • the pharmaceutical composition according to the present invention further comprises at least one suitable adjuvant, such as BCG or alum.
  • suitable adjuvants include Aquila's QS21 stimulon (Aquila Biotech, Worcester, MA, USA) which is derived from saponin, mycobacterial extracts and synthetic bacterial cell wall mimics, and proprietory adjuvants such as Ribi's Detox.
  • Quil A another saponin derived adjuvant, may also be used (Superfos, Denmark).
  • adjuvants such as CpG oligonucleotides, stabilized RNA, Imiquimod (commercially available under the tradename AldaraTM from 3M Pharma, U.S.A.), Incomplete Freund's Adjuvant (commercially available as Montanide ISA-51 from Seppic S.A., Paris, France), liposomal formulations may also be useful. It may also be useful to give the peptide conjugated to keyhole limpet hemocyanin, preferably also with an adjuvant.
  • a pharmaceutical composition that contains at least one collagen binding peptide according to SEQ ID No. 3 to SEQ ID No. 15 according to the invention, a nucleic acid according to the invention, or an antibody according to the invention, and a pharmaceutically acceptable carrier.
  • This composition is used for parenteral administration, such as subcutaneous, intradermal, intraperitoneal, intravenous, intramuscular or oral administration.
  • the peptides are dissolved or suspended in a pharmaceutically acceptable, preferably aqueous carrier.
  • the composition can contain excipients, such as buffers, binding agents, blasting agents, diluents, flavors, lubricants, etc.
  • the peptides can also be administered together with immune stimulating substances, such as cytokines.
  • composition can be used for a prevention, prophylaxis and/or therapy of bacterial, and in particular streptococcal diseases.
  • the pharmaceutical preparation as described containing at least one of the peptides of the present invention comprising SEQ ID No. 3 to SEQ ID No. 15 or an antibody of the present invention is administered to a patient that suffers from a bacterial, and in particular streptococcal disease, in particular rheumatic fever.
  • composition as described that comprises a peptide consisting of amino acid sequences according to SEQ ID No. 3 to SEQ ID No. 15.
  • the pharmaceutical preparation containing at least one of the peptides of the present invention comprising any of SEQ ID No. 3 to SEQ ID No. 15 is administered to a patient that suffers from a bacterial disease that is associated with the respective peptide according to the invention. Thereby, a peptide-specific immune response can be triggered.
  • the dosage of the ligand of the collagen binding peptide, preferably the anti-collagen binding motif antibody, to be administered to a patient suffering from the present diseases will vary with the precise nature of the condition being treated and the recipient of the treatment.
  • the dose will generally be in the range of about 0.1 to about 100 mg for an adult patient, usually administered daily for a period between 1 and 30 days.
  • the preferred daily dose is 1 to 10 mg per day, although in some instances larger doses of up to 40 mg per day may be used.
  • the dosage will be applied in such a manner that the ligand is present in the medicament in concentrations that provide in vivo concentrations of said ligand in a patient to be treated of between 0.01 mg/kg/day and 1 mg/kg/day.
  • Another aspect of the present invention relates to the antibody according to the present invention, or the pharmaceutical composition according to the present invention for use in medicine.
  • Another aspect of the present invention relates to the peptide according to the present invention, the antibody according to the present invention, or the pharmaceutical composition according to the present invention for use in the prevention and/or treatment of streptococcal infections and/or rheumatic fever and/or rheumatic heart disease.
  • Yet another important aspect of the present invention relates to a method for diagnosing a streptococcal infection, rheumatic fever and/or rheumatic heart disease, comprising the steps of a) obtaining a sample from a patient to be diagnosed, and b) detecting the presence and/or the amount of a peptide according to the present invention, an antibody according to the present invention, and/or a nucleic acid according to the present invention in said sample. Further details regarding the diagnosis are well known to the person of skill, and are also described below.
  • Yet another important aspect of the present invention relates to a diagnostic kit for diagnosing a streptococcal infection, rheumatic fever and/or rheumatic heart disease, comprising a peptide according to the present invention, or an antibody according to the present invention, optionally together with suitable labels and dyes.
  • kits containing one or more nucleic acid probes that are specific for the nucleic acids as described, and which can be used for the detection of collagen-binding proteins from bacteria, and in particular of M- and M-like proteins in a sample, or for the diagnosis of related bacterial infections.
  • a kit can also contain the appropriate reagents for hybridizing the probe to the sample and detecting bound probe.
  • the kit contains antibodies specific to the peptide and/or peptides according to the present invention which can be used for the detection of collagen-binding proteins from bacteria, and in particular of M- and M-like proteins as described above.
  • the kit contains one or more, or all of the collagen-binding proteins, or fragments thereof, which can be used for the detection of bacteria or for the presence of antibodies to collagen-binding bacterial proteins in a sample.
  • the kits described herein may additionally contain equipment for safely obtaining the sample, a vessel for containing the reagents, a timing means, a buffer for diluting the sample, and a colorimeter, reflectometer, or standard against which a color change may be measured.
  • the reagents including the protein or antibody, are lyophilized, most preferably in a single vessel. Addition of aqueous sample to the vessel results in volatilization of the lyophilized reagents, causing them to react. Most preferably, the reagents are sequentially lyophilized in a single container, in accordance with methods well known to those skilled in the art that minimize reaction by the reagents prior to addition of the sample.
  • sequences of nucleic acid molecules that selectively hybridize with nucleic acid molecules encoding the collagen-binding proteins of the invention, or portions thereof, such as consensus amino acid motif, as described herein or complementary sequences thereof.
  • selective or “selectively” is meant a sequence which does not hybridize with other nucleic acids. This is to promote specific detection of the collagen binding motif according to the invention. Therefore, in the design of hybridizing nucleic acids, selectivity will depend upon the other components present in a sample.
  • the hybridizing nucleic acid should have at least 70% complementarity with the segment of the nucleic acid to which it hybridizes.
  • the term “selectively hybridizes” excludes the occasional randomly hybridizing nucleic acids, and thus, has the same meaning as “specifically hybridizing”.
  • the selectively hybridizing nucleic acids of the invention can have at least 70%, 80%, 85%, 90%, 95%, 97%, 98%, and 99% complementarity with the segment of the sequence to which they hybridize.
  • probes are meant nucleic acid sequences that can be used as probes or primers for selective hybridization with complementary nucleic acid sequences for their detection or amplification, which probes can vary in length from about 5 to 100 nucleotides, or preferably from about 10 to 50 nucleotides, or most preferably about 18-24 nucleotides. Therefore, the terms “probe” or “probes” as used herein are defined to include “primers”.
  • Isolated nucleic acids are provided herein that selectively hybridize with the species-specific nucleic acids under stringent conditions and should have at least 5 nucleotides complementary to the sequence of interest as described by Sambrook et al., 1989. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y .
  • the composition preferably includes at least two nucleic acid molecules which hybridize to different regions of the target molecule so as to amplify a desired region.
  • the target region can range between 70% complementary bases and full complementarity and still hybridize under stringent conditions.
  • the degree of complementarity between the hybridizing nucleic acid (probe or primer) and the sequence to which it hybridizes is at least enough to distinguish hybridization with a nucleic acid from other bacteria.
  • Described is a method for the prevention and/or treatment of a human subject suffering from a streptococcal infection and/or rheumatic fever and/or rheumatic heart disease which comprises administering to the said subject an effective amount of an agent selected from a peptide according to the invention, an antibody according to the invention, a nucleic acid according to the invention, an expression vector according to the invention, or the pharmaceutical composition according to the invention.
  • an agent selected from a peptide according to the invention, an antibody according to the invention, a nucleic acid according to the invention, an expression vector according to the invention, or the pharmaceutical composition according to the invention.
  • Suitable formulations, routes of administrations and dosages are indicated above and are further laid out in the following examples. Most preferred is the treatment as an anti-rheumatic fever vaccine.
  • SEQ ID No 1 to SEQ ID No 15 show peptide sequences of collagen binding peptides
  • SEQ ID No 3 to SEQ ID No 15 are according to the present invention.
  • Figure 1 shows the binding of radiolabeled collagen IV to GCS and GGS isolates from animal and human infections.
  • A The percentage of collagen binding strains.
  • B Isolates found positive for collagen-binding were tested for the presence of emm and emm -like genes by PCR, using primers of highly conserved sequences (black bar) and the presence of fog was determined by sequencing of the obtained PCR products (hatched bar).
  • Figure 2 shows streptococcal FOG as a collagen binder.
  • SEM Sccanning Electron Micrograph
  • FOG-expressing strain G45 A
  • FOG-negative non-collagen binding strain G50 B
  • C Schematic model of FOG depicting its domain composition and recombinant constructs.
  • D+E Surface plasmon resonance measurement at different concentrations (12.5 ⁇ g/ml; 25 ⁇ g/ml; 50 ⁇ g/ml; 100 ⁇ g/ml) of FOG1-B and FOG1-A, respectively, using collagen IV as the immobilized ligand.
  • Figure 3 shows autoimmune response against collagen IV induced by FOG and M3 -
  • A Mean serum titer against collagen IV of mice immunized with FOG1-B. FOG1-A, M3.5, or PBS, respectively.
  • B Serum titer against collagen IV and FOG1-A of a pool of collagen IV reactive mouse sera determined prior to (black bar) and after pre-absorption with FOGfl-sepharose (hatched bars).
  • Figure 4 shows the identification of PARF as collagen binding motif -
  • A depicts a spot-membrane experiment with radiolabeled collagen IV as soluble ligand.
  • Spots 1 to 40 are immobilized 15mer peptides constituting a 3 amino acid (aa)-shift representing the first 132 aa of the FOG-protein. Strong signals were obtained with peptide 17 to 20, the sequences of which are displayed in (B). The box indicates the amino acid motif that is present in all four peptides.
  • the mutational analysis based on peptide 19 is depicted in (C). Mutations in the given peptide sequences are indicated in bold and underlined letters. In peptide 50 the sequence from aa 58 to aa 166 was rearranged arbitrarily.
  • peptide 19 is shown together with its position in the mature protein (superscript). Amino acids found to be crucial for collagen IV binding in the spot membrane experiments are indicated in bold letters.
  • An alignment of protein FOG1-A and M3 identifies the homologous sequences shown in (E). The respective sequence of FOG is present in peptide 19. This region was subjected to site directed mutagenesis. Performed substitutions in FOGf1 and the results of binding experiments using dot blot and SPR are indicated in a table in (F). These experiments identified the consensus sequence given in (G).
  • Collagen-binding assays - Streptococci were suspended in PBS to give 10 8 bacteria per ml. Then, 2.5 x 10 7 bacteria were incubated with 30 ng (100,000 cpm) of 125 I-labelled collagen IV isolated from placenta (Sigma, Germany) for 45 minutes at room temperature. Bacteria were harvested by centrifugation, washed in phosphate buffered saline (PBS) with 0.05% Tween 20 (PBST), and the pellet was measured in a gamma counter.
  • PBS phosphate buffered saline
  • PBST 0.05% Tween 20
  • Hyaluronic acid (HA) capsule 2.5 x 10 7 was detected by pre-incubating bacteria with either 20 ⁇ l (60 U) hyaluronidase (Applichem, Darmstadt, Germany) or just 20 ⁇ l PBS for 45 min at 37 °C. The bacteria were washed three times in 1 ml PBS prior to the incubation with the radio-labelled collagen. Assays were performed in triplicates within each set of experiments, and experiments were repeated on different days.
  • Electron microscopy - 5 x 10 7 bacteria of G45 (a FOG-positive, collagen-binding strain) and G50 (a non-collagen binding strain) suspended in 500 ⁇ l PBST were incubated with 10 ⁇ g of collagen IV at room temperature for 30 minutes. Samples were washed, fixed and processed for field emission scanning electron microscopy (FESEM) as described before ( K. Dinkla et al., J Clin Invest 11 1, 1905 (Jun. 2003 )).
  • FOG-positive, collagen-binding strain a FOG-positive, collagen-binding strain
  • G50 a non-collagen binding strain
  • FOGfl amino acid residues 1-557
  • FOG1-B represents the first 278 amino acids
  • FOG1-A the first 134 amino acids of the mature FOG protein ( Fig. 2C ).
  • the plasmids coded for fusion proteins that carried an aminoterminal GST-tag. They were expressed in E. coli HB101.
  • E. coli clones containing the plasmids with the desired substitutions were generated using the GeneTailorTM Site Directed Mutagenesis System (Invitrogen) following the manufacturers recommendations.
  • the GST-tag was removed by digesting the proteins with PreScissionTM protease (GE Healthcare) while bound to the affinity matrix, which eluted the untagged FOG proteins.
  • mice - Pathogen free 8 week old female BALB/c mice were immunized intra-peritoneally with an emulsion of 25 - 30 ⁇ g recombinant purified protein in 50 ⁇ l PBS and 50 ⁇ l Freund's incomplete adjuvant per dose at day 1, 7 and 14.
  • Control mice were injected with 50 ⁇ l PBS and 50 ⁇ l Freund's incomplete adjuvant per dose.
  • serum samples of each group were collected and tested in ELISA.
  • 10 ⁇ l serum pool was diluted 1:50 in PBS, and incubated for 1 h with 1 mg GST-FOGfl protein immobilized on glutathione sepharose 4B. Antibodies that bound to the affinity matrix were removed by centrifugation. The supernatant was subjected to ELISA analysis.
  • BSA bovine serum albumin
  • Dot Blots - Ligand overlay assays were performed by spotting the purified recombinant proteins (5 ⁇ g, 1 ⁇ g, or 0.5 ⁇ g) on nitrocellulose. The membrane was blocked for 1 h in PBS containing 5% skimmed milk, followed by a 1 h incubation with radiolabeled collagen IV (200,000 cpm) in PBST. After five washing steps in PBST, filters were dried and placed on radiographic films (Kodak) for autoradiography.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (11)

  1. Peptide isolé se liant au collagène, comprenant une séquence d'acides aminés selon l'une des séquences SEQ ID N° 3 à SEQ ID N° 15, et dans lequel ledit peptide se liant au collagène a une longueur comprise entre 8 et 12 acides aminés, pour une utilisation en médecine.
  2. Peptide se liant au collagène pour une utilisation en médecine selon la revendication 1, dans lequel ledit peptide est constitué d'une séquence d'acides aminés selon l'une des séquences SEQ ID N° 3 à SEQ ID n° 15.
  3. Peptide se liant au collagène pour une utilisation en médecine selon la revendication 1 ou 2, dans lequel ledit peptide comporte des liaisons non peptidiques et/ou dans lequel ledit peptide fait partie d'une protéine de fusion.
  4. Anticorps ou fragment de celui-ci qui réagit immunologiquement avec le peptide se liant au collagène selon la revendication 1 ou 2.
  5. Composition pharmaceutique comprenant au moins un peptide selon l'une quelconque des revendications 1 à 3, ou un anticorps selon la revendication 4, et un vecteur acceptable d'un point de vue pharmaceutique, de préférence comprenant en outre au moins un adjuvant approprié.
  6. Anticorps selon la revendication 4 ou la composition pharmaceutique selon la revendication 5 pour une utilisation en médecine.
  7. Procédé de criblage de ligands du peptide se liant au collagène selon l'une des revendications 1 à 3, comprenant les étapes qui consistent : a) à incuber ledit peptide avec un ligand putatif, b) à mesurer une liaison entre ledit peptide et ledit ligand putatif, et c) à identifier ledit ligand, où ledit ligand inhibe la liaison au collagène dudit peptide, et où ledit ligand est, par exemple, un anticorps ou un fragment de celui-ci qui réagit immunologiquement avec le peptide se liant au collagène.
  8. Peptide selon l'une quelconque des revendications 1 à 3, l'anticorps selon la revendication 4 ou la composition pharmaceutique selon la revendication 5 pour une utilisation dans la prévention et/ou le traitement des infections streptococciques et/ou du rhumatisme articulaire aigu et/ou de la cardite rhumatismale.
  9. Composition pharmaceutique selon la revendication 5 pour une utilisation en tant que vaccin contre le rhumatisme articulaire aigu.
  10. Procédé de diagnostic d'une infection streptococcique, du rhumatisme articulaire aigu et/ou de la cardite rhumatismale, comprenant l'étape qui consiste à détecter la présence et/ou la quantité d'un peptide selon l'une quelconque des revendications 1 à 3, ou d'un anticorps selon la revendication 4, dans un échantillon obtenu d'un patient à diagnostiquer.
  11. Kit de diagnostic pour le diagnostic d'une infection streptococcique, du rhumatisme articulaire aigu et/ou de la cardite rhumatismale, comprenant un peptide selon l'une quelconque des revendications 1 à 3, ou un anticorps selon la revendication 4, facultativement conjointement avec des étiquettes et des colorants appropriés.
EP07725777.2A 2006-06-06 2007-06-01 Peptide associé au rhumatisme articulaire aigu (parf) et son utilisation en tant que marqueur diagnostique Not-in-force EP2029624B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07725777.2A EP2029624B1 (fr) 2006-06-06 2007-06-01 Peptide associé au rhumatisme articulaire aigu (parf) et son utilisation en tant que marqueur diagnostique

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011685A EP1864996A1 (fr) 2006-06-06 2006-06-06 Peptide associé de la fievre rhumatismale et son utilisation comme marquer diagnostique.
PCT/EP2007/004898 WO2007140953A1 (fr) 2006-06-06 2007-06-01 Peptide associé au rhumatisme articulaire aigu (parf) et son utilisation en tant que marqueur dignostique
EP07725777.2A EP2029624B1 (fr) 2006-06-06 2007-06-01 Peptide associé au rhumatisme articulaire aigu (parf) et son utilisation en tant que marqueur diagnostique

Publications (2)

Publication Number Publication Date
EP2029624A1 EP2029624A1 (fr) 2009-03-04
EP2029624B1 true EP2029624B1 (fr) 2014-10-22

Family

ID=37192574

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06011685A Withdrawn EP1864996A1 (fr) 2006-06-06 2006-06-06 Peptide associé de la fievre rhumatismale et son utilisation comme marquer diagnostique.
EP07725777.2A Not-in-force EP2029624B1 (fr) 2006-06-06 2007-06-01 Peptide associé au rhumatisme articulaire aigu (parf) et son utilisation en tant que marqueur diagnostique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP06011685A Withdrawn EP1864996A1 (fr) 2006-06-06 2006-06-06 Peptide associé de la fievre rhumatismale et son utilisation comme marquer diagnostique.

Country Status (4)

Country Link
US (1) US8956612B2 (fr)
EP (2) EP1864996A1 (fr)
JP (1) JP5340926B2 (fr)
WO (1) WO2007140953A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124632A1 (fr) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Nanoparticules assistées par des composés amphiphiles pour délivrance ciblée
FR2915393B1 (fr) 2007-04-27 2012-12-14 Vincience Composition pharmaceutique et/ou cosmetique contenant un principe actif activateur du cytochrome c
FR2915394B1 (fr) * 2007-04-27 2012-12-14 Vincience Composition pharmaceutique et/ou cosmetique contenant des peptides
US8466258B2 (en) * 2007-12-13 2013-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis
GB0918392D0 (en) * 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
JP2022505871A (ja) 2018-10-23 2022-01-14 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体ｆｃ融合タンパク質
EP4138778A1 (fr) 2020-04-22 2023-03-01 Dragonfly Therapeutics, Inc. Formulation, schéma posologique et procédé de fabrication de protéines fusionnées avec fc hétérodimères
WO2022009698A1 (fr) * 2020-07-06 2022-01-13 学校法人東京薬科大学 Peptide et complexe le comprenant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006421A1 (fr) * 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Vaccin a proteine m multivalente recombinee

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280997B1 (en) * 1994-06-10 2001-08-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecule which codes for a 32 KDA protein having 11-CIS retinol dehydrogenase activity, and which associates with P63, a portion of a retinol binding protein receptor
JP3515314B2 (ja) 1997-03-25 2004-04-05 扶桑薬品工業株式会社 ストレプトコッカス・ピオゲネス菌に起因する感染症の診断用プローブ
WO2000075180A2 (fr) * 1999-06-04 2000-12-14 Florian Kern Peptides servant a la vaccination contre le cytomegalovirus humain
US6777547B1 (en) 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
AU2002361559A1 (en) * 2001-09-24 2003-04-28 University Of Pittburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diganostic methods and reagents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006421A1 (fr) * 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Vaccin a proteine m multivalente recombinee

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DINKLA KATRIN ET AL: "Identification of a streptococcal octapeptide motif involved in acute rheumatic fever", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 282, no. 26, 29 June 2007 (2007-06-29), pages 18686 - 18693, XP002613910, ISSN: 0021-9258, [retrieved on 20070423], DOI: 10.1074/JBC.M701047200 *
KATRIN DINKLA ET AL: "Crucial Role of the CB3-Region of Collagen IV in PARF-Induced Acute Rheumatic Fever", PLOS ONE, vol. 4, no. 3, 1 January 2009 (2009-01-01), pages E4666 - E4666, XP055026237, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0004666 *

Also Published As

Publication number Publication date
EP2029624A1 (fr) 2009-03-04
JP2009539357A (ja) 2009-11-19
US8956612B2 (en) 2015-02-17
EP1864996A1 (fr) 2007-12-12
US20100150929A1 (en) 2010-06-17
WO2007140953A1 (fr) 2007-12-13
JP5340926B2 (ja) 2013-11-13

Similar Documents

Publication Publication Date Title
EP2029624B1 (fr) Peptide associé au rhumatisme articulaire aigu (parf) et son utilisation en tant que marqueur diagnostique
US7666582B2 (en) IdeS, an IgG-degrading enzyme of Streptococcus pyogenes
KR101595234B1 (ko) 면역원성 폴리펩타이드 및 단일클론 항체
US7270827B2 (en) Multivalent streptococcal vaccine compositions and methods for use
JP2002516571A (ja) Ｅｎｔｅｒｏｃｏｃｃｕｓ ｆａｅｃａｌｉｓポリヌクレオチドおよびポリペプチド
US20070098737A1 (en) Streptococcal streptolysin S vaccines
JP2009039110A (ja) Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
JP2002531054A (ja) Ｂ群連鎖球菌由来の核酸およびタンパク質
US7160547B2 (en) Streptococcal streptolysin S vaccines
WO2007122400A9 (fr) Nouveaux polypeptides et utilisation de ceux-ci
WO2005019249A2 (fr) Identification de polynucleotides responsables de la virulence de porphyromonas gingivalis dans le diagnostic, le traitement, et la surveillance de maladies parodontales
US20060246083A1 (en) Protective antigen of group a streptococci
WO2004020609A9 (fr) Antigenes streptococcus pneumoniae pour le diagnostic, le traitement et la prevention d'infections evolutives
CA2353802C (fr) Nouvel antigene protecteur de streptococci du groupe a
US20050158345A1 (en) Streptococcal ABC transporter protein
CA2247072A1 (fr) Proteines d'origine bacterienne de fixation sur l'elastine, sequences d'acide nucleique codant ladite proteine et procedes diagnostiques et therapeutiques d'utilisation de cette proteine
WO2003064446A2 (fr) Peptides
WO2005023851A1 (fr) Polypeptides de liaison au plasminogene/a la plasmine et acides nucleiques associes
JPH11253176A (ja) ＭｕｒＦ
US20020061306A1 (en) Streptococcal alpha ZM binding protein
JP2004504056A (ja) タンパク質
JP2002518049A (ja) 複製起点および使用方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081229

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BARROSO, VANESSA

Inventor name: DINKLA, KATRIN

Inventor name: NITSCHE-SCHMITZ, PATRIC, D.

Inventor name: CHHATWAL, GURSHARAN, S.

17Q First examination report despatched

Effective date: 20090420

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/315 20060101AFI20140415BHEP

Ipc: C07K 16/12 20060101ALI20140415BHEP

Ipc: A61K 38/00 20060101ALI20140415BHEP

Ipc: A61K 39/00 20060101ALI20140415BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140527

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 692611

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007038973

Country of ref document: DE

Effective date: 20141204

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20141022

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 692611

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141022

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150222

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150223

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150123

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007038973

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

26N No opposition filed

Effective date: 20150723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150601

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150601

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20160601

Year of fee payment: 10

Ref country code: CH

Payment date: 20160613

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20160516

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20160630

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070601

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141022

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007038973

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170601

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170601

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180103

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630